{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:52:20Z","timestamp":1789426340742,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.medcli.2022.01.024","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T09:47:51Z","timestamp":1651657671000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Artritis psori\u00e1sica"],"prefix":"10.1016","volume":"159","author":[{"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Laiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2022.01.024_bib0325","doi-asserted-by":"crossref","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: A literature review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0330","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ad.2010.01.016","article-title":"Psoriatic arthritis: What the dermatologist needs to know, Part 2","volume":"101","author":"L\u00f3pez-Ferrer","year":"2010","journal-title":"Actas Dermosifiliograf."},{"key":"10.1016\/j.medcli.2022.01.024_bib0335","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","article-title":"Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15,332 patients with psoriatic arthritis. Data from the EuroSpA collaboration","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0340","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.01.024_bib0345","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2010.11.010","article-title":"Osteoclasts in arthritis and Th17 cell development","volume":"11","author":"Okamoto","year":"2011","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0350","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1186\/ar2097","article-title":"HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis","volume":"8","author":"Queiro","year":"2006","journal-title":"Arthritis Res Ther."},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2022.01.024_bib0355","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","article-title":"The many faces of psoriatic arthritis: Their genetic determinism","volume":"59","author":"Winchester","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.024_bib0360","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1136\/annrheumdis-2015-207467","article-title":"ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers","volume":"74","author":"Robinson","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0365","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/art.37885","article-title":"Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis","volume":"65","author":"Apel","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.024_bib0370","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.01.024_bib0375","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/jid.2014.414","article-title":"Gene expression differences between psoriasis patients with and without inflammatory arthritis","volume":"135","author":"Pollock","year":"2015","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0380","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory tissue-resident memory phenotype and function of synovial interleukin-17A+ CD8+ T cells in psoriatic arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0385","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2014-207137","article-title":"RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation","volume":"75","author":"Danks","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0390","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00223-017-0380-2","article-title":"Altered bone remodeling in psoriatic disease: New insights and future directions","volume":"102","author":"Paine","year":"2018","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.medcli.2022.01.024_bib0395","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1038\/ncomms8741","article-title":"Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun."},{"key":"10.1016\/j.medcli.2022.01.024_bib0400","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.111233","article-title":"Development of composite measures for psoriatic arthritis: A report from the GRAPPA 2010 annual meeting","volume":"39","author":"Helliwell","year":"2012","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0405","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3899\/jrheum.200371","article-title":"Effect of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"48","author":"Ogdie","year":"2021","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0410","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/ard.61.6.534","article-title":"Histological assessment of the early enthesitis lesion in spondyloarthropathy","volume":"61","author":"McGonagle","year":"2002","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0415","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2022.01.024_bib0420","doi-asserted-by":"crossref","first-page":"e001150","DOI":"10.1136\/rmdopen-2019-001150","article-title":"Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS)","volume":"6","author":"Mathew","year":"2020","journal-title":"RMD Open."},{"key":"10.1016\/j.medcli.2022.01.024_bib0425","doi-asserted-by":"crossref","first-page":"e001424","DOI":"10.1136\/rmdopen-2020-001424","article-title":"Comparison of the Heel Enthesitis MRI Scoring System (HEMRIS) with clinical enthesitis and local metabolic activity on PET-CT","volume":"6","author":"Kleinrensink","year":"2020","journal-title":"RMD Open."},{"key":"10.1016\/j.medcli.2022.01.024_bib0430","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.3390\/jcm10122604","article-title":"Psoriatic dactylitis: Current perspectives and new insights in ultrasonography and magnetic resonance imaging","volume":"10","author":"Girolimetto","year":"2021","journal-title":"J Clin Med."},{"key":"10.1016\/j.medcli.2022.01.024_bib0435","article-title":"Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis","author":"Dubash","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0440","first-page":"270","article-title":"Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis","volume":"35","author":"Haroon","year":"2017","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0445","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","article-title":"Axial psoriatic arthritis: An update for dermatologists","volume":"84","author":"Gottlieb","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0450","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3899\/jrheum.170146","article-title":"Nail enthesis ultrasound in psoriasis and psoriatic arthritis: A report from the 2016 GRAPPA Annual Meeting","volume":"44","author":"Cunha","year":"2017","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0455","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ad.2020.06.004","article-title":"Dermatologists\u2019 role in the early diagnosis of psoriatic arthritis: Expert recommendations","volume":"111","author":"Belinch\u00f3n","year":"2020","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"key":"10.1016\/j.medcli.2022.01.024_bib0460","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.024_bib0465","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20971889","article-title":"Axial spondyloarthritis and axial psoriatic arthritis: Similar or different disease spectrum?","volume":"12","author":"Benavent","year":"2020","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0470","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.2719","article-title":"AB0824 Which parameters are relevant in the identifying axial involvement in psoriatic arthritis? Results of a survey among ASAS and GRAPPA members","volume":"79","author":"Poddubnyy","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0475","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3899\/jrheum.190923","article-title":"Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: Data from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"48","author":"Mease","year":"2021","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0480","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0485","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/jcm9103262","article-title":"Defining pre-clinical psoriatic arthritis in an integrated dermato-rheumatology environment","volume":"9","author":"Savage","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.medcli.2022.01.024_bib0490","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","article-title":"The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia","volume":"57","author":"Marchesoni","year":"2018","journal-title":"Rheumatology."},{"key":"10.1016\/j.medcli.2022.01.024_bib0495","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/albgv3","article-title":"Ultrasound-aided diagnosis of preclinical phases of psoriatic arthritis in biologic-na\u00efve psoriasis patients with or without arthralgia","author":"Yen","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0500","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: Review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0505","doi-asserted-by":"crossref","first-page":"e001067","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: Clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open."},{"key":"10.1016\/j.medcli.2022.01.024_bib0510","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0515","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0520","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0525","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.024_bib0530","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/jcm9103262","article-title":"Defining pre-clinical psoriatic arthritis in an integrated dermato-rheumatology environment","volume":"9","author":"Savage","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.medcli.2022.01.024_bib0535","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.171411","article-title":"Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: The ULISSE study","volume":"46","author":"Macchioni","year":"2019","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0540","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000472","article-title":"Diffuse idiopathic skeletal hyperostosis (DISH): Where we are now and where to go next","volume":"3","author":"Mader","year":"2017","journal-title":"RMD Open."},{"key":"10.1016\/j.medcli.2022.01.024_bib0545","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: A systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.medcli.2022.01.024_bib0550","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis psoriatic arthritis, and rheumatoid arthritis: A population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0555","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s10067-019-04646-7","article-title":"Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients","volume":"38","author":"Ortolan","year":"2019","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0560","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0565","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10067-015-2960-8","article-title":"Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease","volume":"34","author":"Rosenbaum","year":"2015","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0570","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40744-020-00207-6","article-title":"Depression in psoriatic arthritis: dimensional aspects and link with systemic inflammation","volume":"7","author":"Mathew","year":"2020","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.medcli.2022.01.024_bib0575","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0580","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40744-020-00202-x","article-title":"The impact of comorbidity on patient-reported outcomes in psoriatic arthritis: A systematic literature review","volume":"7","author":"Ca\u00f1ete","year":"2020","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.medcli.2022.01.024_bib0585","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: A systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open."},{"key":"10.1016\/j.medcli.2022.01.024_bib0590","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0595","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2022.01.024_bib0600","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.024_bib0605","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0610","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2022.01.024_bib0615","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.01.024_bib0620","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phaseIII AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.024_bib0625","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.01.024_bib0630","doi-asserted-by":"crossref","unstructured":"Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60:2109-21.","DOI":"10.1093\/rheumatology\/keab119"},{"key":"10.1016\/j.medcli.2022.01.024_bib0635","doi-asserted-by":"crossref","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81:225-31.","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"10.1016\/j.medcli.2022.01.024_bib0640","doi-asserted-by":"crossref","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81:351-8.","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"10.1016\/j.medcli.2022.01.024_bib0645","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phaseIIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:54:45Z","timestamp":1758419685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775322000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0025775322000847"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2022.01.024","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artritis psori\u00e1sica","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2022.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}